Best Investments for 2015
Takeover candidate United Therapeutics fights Sandoz over patents for treating a rare disorder.
In trading on Friday, shares of Aegerion Pharmaceuticals Inc crossed above their 200 day moving average of $28.23, changing hands as high as $28.85 per share. Aegerion Pharmaceuticals Inc shares are currently trading off about 2.1% on the day.
Horizon Pharma (HZNP) shares are up almost double digits following the company's earnings beat and revised fiscal 2015 guidance.
BroadSoft, TG Therapeutics and Ziopharm Oncology also have room for further gains, according to a technical analysis of their recent stock activity.
Cramer says he's a fan of Monster Beverage and Ross Stores after reporting better-than-expected earnings and Clean Harbors' business remains on track as does Receptos' drug plans.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
The most recent short interest data has been released by the NASDAQ for the 02/13/2015 settlement date, which shows a 274,894 share increase in total short interest for Foundation Medicine Inc , to 2,721,905, an increase of 11.23% since 01/30/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
The most recent short interest data has been released by the NASDAQ for the 02/13/2015 settlement date, which shows a 3,870,322 share increase in total short interest for Array BioPharma Inc. , to 23,749,847, an increase of 19.47% since 01/30/2015.
As the Nasdaq approaches the 5,000 mark, the CNBC 'Fast Money Halftime' trading panel examines whether this time is different.
A look at the weighted underlying holdings of the SPDR S&P Biotech ETF (XBI) shows an impressive 18.5% of holdings on a weighted basis have experienced insider buying within the past six months. START SLIDESHOW:10 ETFs With Stocks That Insiders Are Buying » Tesaro Inc , which makes up 1.37% of the SPDR S&P Biotech ETF (XBI), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data.
TheStreet highlights 3 stocks pushing the drugs industry lower today.
TheStreet highlights 3 stocks pushing the drugs industry higher today.
To buy PTC Therapeutics today would cost roughly $3 billion, a significant pile of cash to risk on an investment that could blow up at the end of the year.
Ampio Pharmaceuticals completed a clinical trial of its diabetic macular edema drug Optina in November, but it is just too busy to disclose results.
The following Pall (PLL) conference call took place on February 24, 2015, 08:30 AM ET. This is a transcript of that earnings call:
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a
comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and
strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV